Spotlight On High Doses Again After Pfizer Duchenne Gene Therapy Death

US Regulator May Call For Limits

Dec 23 2021

Earlier safety issues have already delayed Pfizer's Phase III study, which is now expected to read out in early 2023. • Source: Alamy